Comparison Between EGFR-TKI Efficacy in Early-Stage Non-small Cell Lung Cancer and Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis
Lung · 05.08.2026 · 204 (1)
DOI: 10.1007/s00408-026-00918-7 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Lung, online erschienen am 05.08.2026. Verfasst von Bingxue Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Jinling Hospital,Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit nennt 70 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard of care for advanced non-small cell lung cancer (NSCLC). However, their comparative efficacy and safety profile in early-stage versus advanced-stage disease remains systematically unexplored. METHODS: We performed a systematic review and meta-analysis of PubMed, Embase, Cochrane Library, and Web of Science through January 4, 2025. Included studies reported objective response rate (ORR), disease control rate (DCR), or treatment-related adverse events (TRAEs) for EGFR-TKI monotherapy. Pooled estimates were synthesized using a generalized linear mixed model (GLMM). RESULTS: Forty-two studies comprising 46 treatment groups and 3713 patients (343 early-stage; 3370 advanced-stage) were included. EFFICACY: The pooled ORR was significantly higher in advanced-stage NSCLC (0.59, 95% CI 0.51-0.67) than in early-stage disease (0.36, 95% CI 0.15-0.63). In contrast, early-stage disease achieved a higher DCR (0.95 vs. 0.89). SAFETY: Early-stage patients experienced a significantly lower incidence of Grade ≥3 TRAEs compared to those with advanced disease (8.0% vs. 21%). CONCLUSION: EGFR-TKIs provide superior tumor shrinkage (ORR) in advanced NSCLC, the reasons remain uncertain, whereas early-stage disease achieves better disease stability (DCR) with significantly enhanced tolerability. These findings suggest that stage-specific strategies-potentially combining TKIs with other modalities in early stages-are necessary to optimize clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Jinling Hospital,Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Department of Respiratory and Critical Care Medicine,Jinling Hospital, Medical School of Southeast University, Nanjing, China.
- Department of Respiratory and Critical Care Medicine, Jinling Clinical Medical College,Nanjing Medical University, Nanjing, China.
- Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Respiratory and Critical Care Medicine, Jinling Hospital,Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. netlhb@126.com.
Zitieren
APA
Wang, B., Yao, Y., Chen, Z., Wu, R., Sun, J., Li, X., Xu, X., Si, Y., & Liu, H. (2026). Comparison Between EGFR-TKI Efficacy in Early-Stage Non-small Cell Lung Cancer and Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis. Lung, 204(1). https://doi.org/10.1007/s00408-026-00918-7
Vancouver
Wang B, Yao Y, Chen Z, Wu R, Sun J, Li X, et al. Comparison Between EGFR-TKI Efficacy in Early-Stage Non-small Cell Lung Cancer and Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis. Lung. 2026;204(1). doi:10.1007/s00408-026-00918-7
BibTeX
@article{Wang2026,
author = {Wang, Bingxue and Yao, Yang and Chen, Zhangxuan and Wu, Ranpu and Sun, Jiajie and Li, Xinjing and Xu, Xuanhao and Si, Yunxiao and Liu, Hongbing},
title = {Comparison Between EGFR-TKI Efficacy in Early-Stage Non-small Cell Lung Cancer and Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis},
journal = {Lung},
year = {2026},
volume = {204},
number = {1},
doi = {10.1007/s00408-026-00918-7}
}
EUVIMED